Early Onset Alzheimer’s: Dian-Tu Trial

0

ST. LOUIS, Mo. (Ivanhoe Newswire) — Alzheimer’s disease is devastating for patients, their families and friends. For many, symptoms begin to appear when a person is in his or her sixties or seventies. But, a small percentage of people begin to show signs in their fifties, forties, and even thirties. Researchers are studying new therapies that may slow progression in these younger patients.

Marty Reiswig is a husband, a father of two, and a realtor. He believes in making the very best of every day, for good reason…

“At 38, I know I may only have another 12 years of good mental capacity,” Reiswig told Ivanhoe.

Marty came face-to-face with his family’s genetic fate more than a decade ago. At one reunion, there were very few relatives over 60.  He and Jaclyn had just started dating.

“He saw an uncle who was clearly having problems. That’s when it became clear to him. He took me for a walk and said if you want out now, I understand,” Jaclyn explained.

“Without skipping a beat she said, ‘I’d rather have 30 good years with you, than a lifetime with anybody else’,” continued Marty.

Eric McDade, DO is a Neurologist and Assistant Professor in the Department of Neurology at Washington University at St. Louis School of Medicine, studying the familial early onset of Alzheimer’s. It is known as the Dominantly Inherited Alzheimer Network Trials Unit; or DIAN-TU. Researchers are focused on defects in three genes.

“These genetic changes are actually passed in a way that each generation from somebody who has the gene, has a 50-50 chance of getting the gene defect,” Dr. McDade explained to Ivanhoe. (Read Full Interview)

People who inherit the defective gene almost always develop Alzheimer’s at a young age. Marty’s father developed symptoms at  52. As part of the study, Marty had genetic testing. For now, he and Jaclyn have opted not to know the results.

Marty explained, “The burden of finding out that I do have the gene would be far worse and heavy and difficult than not knowing.”

The current trials are using drugs that attack different forms of the amyloid protein, associated with Alzheimer’s.

“My hope for this study is that it gives us an opportunity to live and enjoy life just five or ten more years,” Marty stated.

Marty says although he does not know if he carries the genetic defect, he is proactive about what he can do to delay the potential onset. Marty and his brother are both enrolled in the DIAN-TU trials. Researchers at sites in the U.S., Canada, Australia and Europe will be enrolling participants in a third arm of the trial, which will test a daily oral medication.  For more information visit www.dianexr.org.

Contributors to this news report include: Cyndy McGrath, Supervising and Field Producer; Gabriella Battistiol, Assistant Producer; Roque Correa, Editor and Videographer.

To receive a free weekly e-mail on Medical Breakthroughs from Ivanhoe, sign up at: http://www.ivanhoe.com/ftk

 

MEDICAL BREAKTHROUGHS

RESEARCH SUMMARY

TOPIC: EARLY ONSET ALZHEIMER’S: DIAN-TU TRIAL

REPORT: MB #4278

BACKGROUND: Early onset Alzheimer’s is an uncommon form of dementia that can strike in people younger than age 65. About 5 percent of all the people who have Alzheimer’s disease develop symptoms before age 65. While around 4 million Americans have Alzheimer’s, at least 200,000 of those people have early onset. Most people who experience early onset start developing symptoms and show signs of the disease in their fifties or even as early as their forties and thirties.  Experts cannot pinpoint why some people get the disease at a younger age, but others with early onset have the type classified as “familial Alzheimer’s disease.” This means they are likely to have a grandparent or parent who also experiences early onset Alzheimer’s.  Accurate diagnosis is critical, to rule out other issues and seek the most appropriate treatment. It can be fundamental for the family to understand and respond appropriately to the situation, as well as informing employers and others in a patients life.
(Source: http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048356)

COPING: There is no cure for Alzheimer’s, and it has a tremendous impact on a person; however, those who develop young onset face uniquely different challenges than those who are older, since they are most likely still more involved in a career, and taking care of a family. Due to their young age, some people may deny or question the diagnosis.  At work they may want to cut back on their hours, or decrease their task load so as to not overwhelm themselves. You may want to seek counseling, and when it comes to children, find activities you can enjoy together. Stay engaged and honest with the kids, and find support groups or record your thoughts, feelings and experiences for them to save. There are plenty of resources online to help cope with Alzheimer’s.

(Source: http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048356?pg=2)

NEW STUDY: The Dominantly Inherited Alzheimer Network Trials Unit, or DIAN-TU researchers are focusing on defects in three genes. Most people who inherit these three gene mutations develop Alzheimer’s disease in their forties and fifties. The current trials are using drugs that attack different forms of the amyloid protein, which is associated with Alzheimer’s. This can help researchers understand how to better treat and better diagnose the disease at an earlier stage. All subjects in the trial are individuals who are either known to have this genetic mutation that causes early onset, or who are unaware of their genetic status but have a sibling or parent with the known genetic mutation. The investigators are testing the three experimental drugs, gantenerumab, solanezumab, and JNJ-54861911, to assess the safety, side effects, and impact on imaging and fluid biomarkers. Subtle, early changes in cognition will also be evaluated; those participants at the stage they are recruited are unlikely to have more than minimal changes during the study. The study is being funded by The National Institute of Health, The Alzheimer’s Association, and Eli Lilly and Co., Hoffman-La Roche and Janssen Pharmaceuticals.

(Source: https://www.nia.nih.gov/alzheimers/clinical-trials/dominantly-inherited-alzheimer-network-trial-opportunity-prevent-dementia)

FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT:

Attn: Ellen Ziegemeier

www.dianexr.org

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at mthomas@ivanhoe.com

Doctor Q and A

Read the entire Doctor Q&A for Eric McDade, DO

Read the entire Q&A